Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P35716
UPID:
SOX11_HUMAN
Alternative names:
-
Alternative UPACC:
P35716; Q4ZFV8
Background:
Transcription factor SOX-11 plays a pivotal role in the regulation of gene expression, acting as a transcriptional activator. It binds cooperatively with other factors to gene promoters, enhancing transcriptional activation. SOX-11's involvement in cell survival and organogenesis, particularly in the neural tube, branchial arches, and somites, underscores its importance in developmental processes.
Therapeutic significance:
SOX-11's association with Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism highlights its potential as a therapeutic target. Understanding the role of Transcription factor SOX-11 could open doors to potential therapeutic strategies.